Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Jennie H Best,1 Amanda M Kong,2 David M Smith,2 Ibrahim Abbass,1 Margaret Michalska1 1Genentech, Inc., South San Francisco, CA, USA; 2IBM Watson Health, Cambridge, MA, USACorrespondence: Jennie H BestGenentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USATel +1 858 361-4937Email best.jennie@g...
Main Authors: | Best JH, Kong AM, Smith DM, Abbass I, Michalska M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-12-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/healthcare-costs-of-potential-glucocorticoid-associated-adverse-events-peer-reviewed-article-CEOR |
Similar Items
-
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database
by: Jennie H. Best, et al.
Published: (2019-10-01) -
Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients Affected by Giant Cell Arteritis
by: Paul Castan, et al.
Published: (2022-02-01) -
Biologic Therapies for Giant Cell Arteritis
by: Harrington R, et al.
Published: (2021-01-01) -
Advances in the Treatment of Giant Cell Arteritis
by: Santos Castañeda, et al.
Published: (2022-03-01) -
Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study
by: Luca Quartuccio, et al.
Published: (2020-01-01)